nxp900
nxp900: sourced relationships with 1 company · 3 clinical trials tracked.
nxp900 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could nxp900 → NVCT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Nuvectis Pharma, Inc. (NVCT) Advanced Solid Tumor; EGFR Mutation Positive Non-small Cell … | Phase 1 |
Clinical Trial Registry Records (3)
A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer
Primary endpoint: Number of patients with treatment related adverse events and/or clinical laboratory abnormalities
A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
Primary endpoint: Number of patients with treatment related adverse events and/or clinical laboratory abnormalities
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Primary endpoint: Number of patients with treatment related adverse events and/or clinical laboratory abnormalities
Frequently asked questions
Which companies have sourced relationships with nxp900?
nxp900 has dated SEC/FDA relationship records for Nuvectis Pharma, Inc..
How many clinical trials involve nxp900?
BioSniper tracks 3 clinical trials involving nxp900.